Edesa Biotech, Inc.
Business
Edesa Biotech is a biopharmaceutical company developing treatments for inflammatory and immune-related diseases. The company's pipeline focuses on Medical Dermatology (EB06, a monoclonal antibody for vitiligo; EB01, a topical cream for allergic contact dermatitis) and Respiratory (EB05/paridiprubart, a TLR4-blocking antibody for acute respiratory distress syndrome). The company in-licenses clinical-stage assets from academic institutions and other biopharmaceutical companies, conducts clinical development through partnerships with contract research organizations and contract manufacturing organizations.
Summary from 10-K filed 2025-12-12
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Research and development | 4 | 3 | 5 | 13 | 18 | |
| General and administrative | 4 | 4 | 4 | 5 | 6 | |
| Loss from operations | −8 | −7 | −9 | −18 | −24 | |
| Reimbursement grant income | 783,894 | 698,277 | 581,039 | — | — | |
| Interest income | 2,558 | 153,498 | 289,846 | 63,523 | 11,165 | |
| Misc other income | 0 | 14,766 | 0 | — | — | |
| Foreign exchange loss | −59,609 | −21,042 | −21,742 | −21,114 | −13,022 | |
| Nonoperating Income (Expense) | 726,843 | 845,499 | 849,143 | 822,666 | 10 | |
| Loss before income taxes | −7 | −6 | −8 | −18 | −13 | |
| Income tax expense | 800 | 800 | 800 | 800 | 800 | |
| Net loss | −7 | −6 | −8 | −18 | −13 | |
| Exchange differences on translation | 76,842 | −27,965 | −1,046 | −8,340 | 81,942 | |
| Net comprehensive loss | −7 | −6 | −8 | −18 | −13 | |
| Weighted average number of common shares (in shares) | 6 | 3 | 3 | — | — | |
| Loss per common share - basic and diluted (in dollars per share) | −1.27 | −1.93 | −2.93 | — | — |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 11 | 1 | 5 | 7 | 8 | |
| Accounts and other receivable | 642,866 | 270,908 | 626,543 | 1 | 3 | |
| Prepaid expenses and other current assets | 77,838 | 367,394 | 448,912 | 745,543 | 948,645 | |
| Total current assets | 12 | 2 | 6 | 9 | 12 | |
| Long-term deposits | 39,966 | 41,151 | 173,490 | 171,464 | — | |
| Intangible asset, net | 2 | 2 | 2 | 2 | 2 | |
| Right-of-use assets | 0 | 18,361 | 91,373 | 18,465 | 96,571 | |
| Total assets | 14 | 4 | 9 | 12 | 15 | |
| Current liabilities: | 1 | 2 | 2 | 2 | 1 | |
| Short-term right-of-use lease liabilities | 0 | 19,867 | 74,714 | 18,975 | 78,808 | |
| Total current liabilities | 1 | 2 | 2 | 2 | 1 | |
| Authorized unlimited common and preferred shares without par value issued and outstanding: 7,141,783 common shares (September 30, 2024 - 3,247,389) | 55 | 47 | 47 | — | 35 | |
| Additional paid-in capital | 15 | 14 | 13 | 11 | 5 | |
| Accumulated other comprehensive loss | −165,771 | −242,613 | −214,648 | −213,602 | −205,262 | |
| Accumulated deficit | −66 | −59 | −52 | −44 | −26 | |
| Total shareholders' equity | 12 | 2 | 7 | 9 | 13 | |
| Total liabilities and shareholders' equity | 14 | 4 | 9 | 12 | 15 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-09-30 | FY 2024 2024-09-30 | FY 2023 2023-09-30 | FY 2022 2022-09-30 | FY 2021 2021-09-30 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 119,273 | 186,049 | 183,471 | — | — | |
| Share-based compensation | 729,642 | 537,492 | 1 | 2 | 3 | |
| Gain on loan forgiveness | 0 | −14,766 | 0 | — | — | |
| Accounts and other receivable | −377,987 | 356,339 | 562,770 | 2 | — | |
| Prepaid expenses and other current assets | 107,832 | 197,136 | 301,504 | −19,497 | — | |
| Accounts payable and accrued liabilities | −715,499 | 17,590 | −556,270 | 882,843 | −124,724 | |
| Net cash used in operating activities | −7 | −5 | −7 | −12 | −14 | |
| Proceeds from issuance of common shares and warrants | 8 | 729,387 | 4 | 12 | 41,981 | |
| Proceeds from issuance of Series A-1 preferred shares and warrants | 2 | 0 | — | — | — | |
| Payment for issuance costs of warrants | −23,446 | 0 | — | — | — | |
| Repayment of debt | 0 | −29,532 | 0 | — | — | |
| Net cash provided by financing activities | 17 | 592,031 | 5 | 12 | 14 | |
| Effect of exchange rate changes on cash and cash equivalents | 46,216 | −25,903 | 76,850 | — | — | |
| Net change in cash and cash equivalents | 10 | −4 | −2 | −748,340 | 625,564 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Edesa Biotech, Inc.'s CIK number?
Edesa Biotech, Inc.'s SEC CIK number is 0001540159 (1540159). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Edesa Biotech, Inc.'s SEC filings?
All of Edesa Biotech, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Edesa Biotech, Inc. last report earnings?
Edesa Biotech, Inc. (EDSA) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001171843-26-003429). This is Edesa Biotech, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Edesa Biotech, Inc.'s most recent earnings 8-K?
Edesa Biotech, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001171843-26-003429. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Edesa Biotech, Inc.'s latest earnings 8-K →
Look up any company's CIK number →